Global News

The many roles that contribute to patient recruitment

Monday, August 22, 2016

The Pulse on Patient Recruitment by Ashley Tointon

Recruiting patients into a clinical trial takes careful planning and flawless execution from multiple sources. Although the site is often responsible for contributing the majority of patients needed to meet enrollment targets, there is not one single person or role that is ultimately responsible for patient recruitment. Principal investigators, study coordinators, clinical research associates (CRAs), sponsors, CROs, feasibility analysts, patient recruitment specialists and consultants all play a role.

[Read More]

Cerulean reduces workforce

Friday, August 19, 2016

Cerulean Pharma, a clinical-stage company developing nanoparticle-drug conjugates (NDCs), is reducing its workforce by approximately 48%, to a total of 23 full-time equivalent employees, under a plan expected to be substantially completed by the end of 2016. This workforce reduction is designed to reduce operating expenses while the company refocuses its clinical strategy for CRLX101. Affected employees are being offered severance and outplacement assistance.

[Read More]

10 Tips for Enabling Better CRO-Sponsor Collaborations

Thursday, August 18, 2016

By Craig Morgan, brand development director at goBalto Inc.

By 2020[1] 72% of clinical trials are anticipated to be outsourced, up from just 23% in 2012. Sponsors are seeking cost reductions, access to specialized knowledge, and increased speed and agility. Meanwhile, CROs focus is on business goals related to economic outcomes for their owners, investors and shareholders. Each group is expecting deliverables and timelines to be met or exceeded for potentially different business reasons, leading to a traditional client/vendor-type relationship. Though alliances and partnerships are increasing, there continues to be a client/vendor mentality at the operational and management levels, which perpetuates a lack of trust and empowerment.

[Read More]

Crown Bioscience Oncology Center in San Diego expands services

Wednesday, August 17, 2016

Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has expanded its oncology services with new models, cell lines and assays at its Center of Excellence for Oncology in San Diego.

[Read More]

CROs Pharma Start, H2O Clinical to merge

Monday, August 15, 2016

H2O Clinical, based in Hunt Valley, Maryland and Northbrook, Illinois-based Pharma Start, have announced plans to merge. The CROs, which provide a range of outsourced research services to the pharmaceutical industry, already have a history of close collaboration. Each company will continue to operate as it has in the past, and there will be no disruption to current operations or customer contracts. 

[Read More]

Illumina, FlowJo partner for single cell genomics

Monday, August 15, 2016

Illumina and FlowJo have partnered to develop and co-market analysis software for single cell next-generation sequencing (NGS) data. Under the agreement FlowJo, the producer of FlowJo, software for single cell analysis, will develop a new software application. It will provide additional secondary and tertiary analysis and visualization of datasets with an intuitive approach built on 19 years of experience working with cell biologists and immunologists in single cell phenotyping. The application will seamlessly integrate with Illumina’s Single Cell RNA BaseSpace app, and provide a solution accelerating discovery.

[Read More]

Sekisui XenoTech expands hepatotoxicity testing

Monday, August 15, 2016

Sekisui XenoTech has added additional hepatotoxicity screening assays and methodologies to the company’s existing cytotoxicity contract research services. Cytotoxicity studies assess the risk that test articles may cause toxicity in cells, with hepatotoxicity specifically related to the liver.

[Read More]